Zobrazeno 1 - 10
of 55
pro vyhledávání: '"David Wai Meng Tai"'
Autor:
Choong-kun Lee, Changhoon Yoo, Jung Yong Hong, Se Jun Park, Jin Won Kim, David Wai Meng Tai, Hyeyeong Kim, Krittiya Korphaisarn, Suebpong Tanasanvimon, San-Chi Chen, Ju Won Kim, Ilhwan Kim, Moonho Kim, Joan Choo, Sang-Bo Oh, Ching-Tso Chen, Woo Kyun Bae, Hongsik Kim, Seok Jae Huh, Chia-Jui Yen, Sejung Park, Dong Ki Lee, Landon Long Chan, Beodeul Kang, Minsu Kang, Raghav Sundar, Hye Jin Choi, Stephen Lam Chan, Hong Jae Chon, Myung-Ah Lee
Publikováno v:
Liver Cancer, Pp 1-15 (2024)
Introduction: Atezolizumab plus bevacizumab is a commonly used first-line regimen for advanced hepatocellular carcinoma (HCC) treatment owing to its superior outcomes compared to sorafenib. However, optimal subsequent treatment options for patients w
Externí odkaz:
https://doaj.org/article/48cd992dee674cbb8551afa29b350663
Autor:
Kennedy Yao Yi Ng, Sze Huey Tan, Jack Jie En Tan, Desiree Shu Hui Tay, Ailica Wan Xin Lee, Andrea Jing Shi Ang, Lawrence Wen Jun Wong, Su Pin Choo, David Wai-Meng Tai, Joycelyn Jie Xin Lee
Publikováno v:
Liver Cancer, Pp 1-13 (2021)
Introduction: Development of immune-related adverse events (irAEs) has been associated with enhanced efficacy with the use of immune checkpoint inhibitors (ICIs). It remains unknown whether such an association exists in advanced hepatocellular carcin
Externí odkaz:
https://doaj.org/article/496d27c9aa9f4d5e9ef0778f2382933a
Autor:
Khi Yung Fong, Joseph Jonathan Zhao, Rehena Sultana, Joycelyn Jie Xin Lee, Suat Ying Lee, Stephen Lam Chan, Thomas Yau, David Wai Meng Tai, Raghav Sundar, Chow Wei Too
Publikováno v:
Liver Cancer (2022)
Introduction: Sorafenib was historically the standard of care for advanced hepatocellular carcinoma (aHCC) until it was superseded by the combination of atezolizumab and bevacizumab. Thereafter, several novel first-line combination therapies have dem
Externí odkaz:
https://doaj.org/article/8acd990a891043b68eeb453237bb5c8a
Autor:
Kennedy Yao Yi Ng, Lawrence Wen Jun Wong, Andrea Jing Shi Ang, Ailica Wan Xin Lee, Desiree Shu Hui Tay, Jack Jie En Tan, Sze Huey Tan, Su Pin Choo, David Wai‐Meng Tai, Joycelyn Jie Xin Lee
Publikováno v:
Asia-Pacific Journal of Clinical Oncology. 19:312-319
Combination therapy with immune checkpoint inhibitor (ICI) and antivascular endothelial growth factor (anti-VEGF) is currently the first line treatment for advanced hepatocellular carcinoma (aHCC). However, there are many patients who may not be able
Autor:
Patrick Tan, Khay Guan Yeoh, Jeanie Wu, Ming-Hui Lee, David Wai-Meng Tai, Matthew C.H. Ng, Hyun Cheol Chung, Minkyu Jung, Hyo-Song Kim, Chee-Seng Tan, Asim Shabbir, Jimmy Bok-Yan So, Raghav Sundar, Bernadette Reyna Asuncion, Shi-Hui Tan, Vivien Koh, Nicholas L. Syn, Su-Pin Choo, Iain Bee-Huat Tan, Sun Young Rha, Wei Peng Yong
3G study protocol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9d76726e3b0f81750a5aca82fa967be6
https://doi.org/10.1158/1078-0432.22474659.v1
https://doi.org/10.1158/1078-0432.22474659.v1
Autor:
Philip He, Robin Kate Kelley, Ho Yeong Lim, Takuji Okusaka, Thomas Yau, David Wai-Meng Tai, Ghassan K. Abou-Alfa, Masafumi Ikeda, Bruno Sangro, Yoon-Koo Kang, Silvia Damian, Johanna C. Bendell, Mitesh J. Borad, William P. Harris, Tae-You Kim, Shukui Qin, Alejandra Negro, Mallory Makowsky, Nathan Standifer, Masatoshi Kudo, Ann-Lii Cheng, Jordi Bruix, Antonio Gasbarrini, Wei Peng Yong
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 39, iss 27
PURPOSE This phase I/II study evaluated tremelimumab (anticytotoxic T-lymphocyte–associated antigen-4 monoclonal antibody) and durvalumab (antiprogrammed death ligand-1 monoclonal antibody) as monotherapies and in combination for patients with unre
Autor:
Min-Hee Ryu, Sook Ryun Park, Baek-Yeol Ryoo, David Wai-Meng Tai, Han Chu Lee, Danbi Lee, Young-Suk Lim, Kang Mo Kim, Stephen L. Chan, Joycelyn Lee, Changhoon Yoo, Ju Hyun Shim, J.H. Kim
Publikováno v:
Liver Cancer, Vol 10, Iss 2, Pp 107-114 (2021)
Liver Cancer
Liver Cancer
Introduction: Atezolizumab-bevacizumab is the new standard of care for first-line treatment of advanced hepatocellular carcinoma (HCC). However, the optimal sequence of therapy after disease progression on atezolizumab-bevacizumab is unclear. Methods
Autor:
Xin Hui Chew, Choon Hua Thng, Eshani N. Mathew, Su Pin Choo, Ashley W.Y. Ng, M Wang, Rehena Sultana, Aaron Kian Ti Tong, Han Chong Toh, Sum Leong, Nanda Kumar Karaddi Venkatanarasimha, Pierce K. H. Chow, Chow Wei Too, Kelvin Siu Hoong Loke, Apoorva Gogna, Sue Ping Thang, Wan Ying Chan, Sean Xuexian Yan, Richard Hoau Gong Lo, Brian K. P. Goh, David Chee Eng Ng, Fiona N.N. Moe, Marjorie T.Q. Hoang, Kiat Hon Lim, Jaclyn H. M. Chan, Wanyi Kee, Farah Gillan Irani, Jacelyn S.S. Chua, David Wai-Meng Tai, Aldwin D. Ong, Reiko W.T. Ang
Publikováno v:
Liver Cancer
Liver Cancer, Pp 1-16 (2021)
Liver Cancer, Pp 1-16 (2021)
Introduction: Real-world management of patients with hepatocellular carcinoma (HCC) is crucially challenging in the current rapidly evolving clinical environment which includes the need for respecting patient preferences and autonomy. In this context
Background Hepatocellular carcinoma (HCC) is the most common liver cancer globally, claiming nearly 1 million lives each year. Overexpression of fibroblast growth factor (FGF) receptors (FGFRs) signaling cascade has been shown to contribute to tumori
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8426b0da8055e50c1eb7eb6a8093e396
https://doi.org/10.21203/rs.3.rs-343037/v1
https://doi.org/10.21203/rs.3.rs-343037/v1
Autor:
Richard Lo, Tiffany Hennedige, Chee Kian Tham, Neslihan Arife Kaya, Tony Kiat Hon Lim, Si-Lin Koo, David Wai-Meng Tai, Matthew C.H. Ng, Apoorva Gogna, Hian Liang Huang, Kelvin Siu Hoong Loke, Brian K. P. Goh, David Chee Eng Ng, Sze Huey Tan, Alexander Y. F. Chung, Chow Wei Too, Hui Shan Chong, Joycelyn Lee, Choon Hua Thng, Chung Yip Chan, Nanda Venkatanarasimha, Joe Yeong, Justina Yick Ching Lam, Jia Qi Lim, Farah Gillan Irani, Weiwei Zhai, Su Pin Choo, Han Chong Toh, Pierce K. H. Chow, George Boon-Bee Goh
Publikováno v:
SSRN Electronic Journal.
Proposed short titleY90-Resin Microspheres Radioembolization Followed by Nivolumab in Advanced Hepatocellular CarcinomaBackground : Nivolumab (N) and Y90-resin microspheres radioembolization (Y90-RE) aretherapeutic options in advanced hepatocellular